Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today

Zinger Key Points
  • Vivos Therapeutics shares are trading lower by 25% Thursday morning.
  • The company announced a $4.3 million registered offering.

Vivos Therapeutics Inc VVOS shares are trading lower by 26.1% to $3.05 during Thursday’s session after the company announced a $4.3 million registered offering of 1.36 million shares of common stock at $3.15 per share.

The direct offering is expected to close on September 20, pending standard closing conditions, and will generate approximately $4.3 million in gross proceeds. H.C. Wainwright & Co. is the exclusive placement agent for the offering.

Vivos says the company plans to use the net proceeds for working capital and general corporate purposes. Additionally, no stock purchase warrants are included in the offering.

Read Also: Bank Stocks Hit Inflection Point After Fed’s 50 Basis Point Cut, Analyst Reveals Top Picks

Is VVOS A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Vivos Therapeutics‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. Vivos Therapeutics does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

For example, if you're looking to earn an annualized return of 23.1%, you'll need to buy a share of North American Finl 15 by the Sep. 30, 2024. Once done, you can expect to receive a nominal payout of $0.11 on Oct. 10, 2024.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Vivos Therapeutics will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

According to data from Benzinga Pro, VVOS has a 52-week high of $48.79 and a 52-week low of $1.91.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Newswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!